How should vitamin D be repleted in a patient with a serum 25‑hydroxyvitamin D level of 7 ng/mL?

Vitamin D Repletion for Severe Deficiency (7 ng/mL)

For a patient with a 25-hydroxyvitamin D level of 7 ng/mL, treat with 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, followed by maintenance therapy of 1500-2000 IU daily. 1

Treatment Algorithm

Initial Repletion Phase (8 weeks)

The Endocrine Society guideline provides the standard approach for severe deficiency:

• Standard dosing: 50,000 IU weekly for 8 weeks
• Alternative: 6000 IU daily for 8 weeks (equivalent total dose)
• Target: Achieve 25(OH)D level above 30 ng/mL 1

This regimen delivers approximately 400,000 IU total over 8 weeks and is effective in correcting deficiency in most adults.

Dose Adjustments for Special Populations

Obese patients require 2-3 times higher doses:

• Use 6000-10,000 IU daily during repletion
• Maintenance: 3000-6000 IU daily 1

Research supports that patients with BMI >25 kg/m² achieve target levels less reliably with standard dosing—only 66% vs 85% in normal-weight patients 2. At a level of 7 ng/mL, if the patient is obese, strongly consider the higher dosing range from the outset.

Patients on medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids, other steroid xenobiotic receptor activators) also need 2-3 times higher doses 1.

Maintenance Phase (After Week 8)

• Standard maintenance: 1500-2000 IU daily 1
• Obese/malabsorption/medication patients: 3000-6000 IU daily 1
• Alternative: 50,000 IU every 2 weeks has been shown effective in maintaining levels between 35-50 ng/mL 1

Monitoring Strategy

Recheck 25(OH)D level 10 days after completing the 8-week repletion course to confirm adequate response. Research demonstrates that levels plateau by weeks 8-12 with consistent dosing 3.

Non-Responders

If the patient fails to show adequate increase in 25(OH)D after 8 weeks of compliant treatment, evaluate for:

• Malabsorption disorders: celiac disease, occult cystic fibrosis 1
• Medication interactions
• True non-compliance

Formulation Considerations

Cholecalciferol (vitamin D3) is preferred over ergocalciferol (vitamin D2) due to better adherence (87% vs 68% medication possession ratio) 4. Both are effective biochemically, but the practical advantage of D3 matters in real-world adherence.

Common Pitfalls

1. Underestimating obesity impact: A 7 ng/mL level in an obese patient will likely require higher doses from the start
2. Inadequate maintenance: Nearly half of patients fall below 30 ng/mL by 2-3 months after repletion if maintenance dosing is insufficient 2
3. Starting maintenance too late: Begin maintenance dosing immediately after completing the 8-week repletion course
4. Not monitoring calcium in high-risk patients: Those with granulomatous diseases, lymphoma, or primary hyperparathyroidism need calcium monitoring during repletion 1

Dosing Schedule Flexibility

Research shows that daily, weekly, and bi-weekly schedules achieve similar steady-state levels when cumulative doses are equivalent 3. Choose the schedule based on patient preference and adherence likelihood:

• Daily: Better for patients who take other daily medications
• Weekly: Convenient for most patients, well-studied
• Bi-weekly: Acceptable for maintenance phase

Avoid very large intermittent doses (>100,000 IU at once) in routine practice, as equivalence for long-term clinical outcomes has not been established 5.

Important Context

The 2024 Endocrine Society update 6 notes uncertainty about optimal 25(OH)D thresholds for extra-skeletal outcomes, but the musculoskeletal rationale for treating severe deficiency (7 ng/mL) remains strong, particularly for preventing osteomalacia, maintaining muscle function, and reducing fracture risk in vulnerable patients 5.